|RXII -- USA Stock|| |
USD 2.30 0.04 1.71%
IR Contact Officer
We currently do not have informatin regarding Tamara McGrillen. This executive tanure with RXi Pharmaceuticals Corporation is not currenlty determined.
The company has return on total asset (ROA)
of (66.92) %
which means that it has lost $66.92 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (196.28) %
meaning that it created substantial loss on money invested by shareholders.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 15 people.RXi Pharmaceuticals Corporation (RXII) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 15 people. RXi Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
RXi Pharmaceuticals Leadership Team
|Geert Cauwenbergh, CEO, Ph.D|
|Robert Bitterman, Director, MBA|
|Pamela Pavco, Executive, Ph.D|
|Keith Brownlie, Director|
|Jonathan Freeman, Director, MBA|
|Gerrit Dispersyn, Executive|
|Curtis Lockshin, Director, Ph.D|
|Paul Dorman, Director|
|Alexey Eliseev, Executive|
|Tamara McGrillen, Executive|
Stock Performance Indicators